Disclosure: This site may earn affiliate commissions when you click provider links. This doesn't affect our recommendations. Learn more
Denied Wegovy or Zepbound coverage? A step-by-step appeal playbook covering peer-to-peer review, internal appeals, external review, and cash-pay fallbacks.
A denial letter is not a verdict. Insurance companies deny a significant share of prior authorization requests for Wegovy and Zepbound, often on technical grounds that a well-documented appeal can overturn. The federal appeal framework was strengthened again in January 2026, when new CMS rules took effect requiring faster decisions and specific written reasons for every denial (CMS, 2024). If you have a denial letter in hand, you have a real path forward, and the steps below are how to walk it.
The single biggest predictor of a successful appeal is whether you respond to the specific reason cited in the denial with the specific clinical documentation that addresses it. Generic "please reconsider" letters rarely work. A targeted, evidence-based packet does. If you would rather have a telehealth team that already knows this playbook handle the paperwork, Ro is the provider in our network that most actively supports prior authorization and appeal documentation for both Wegovy and Zepbound.
Answer 10 questions and get a personalized recommendation.
Take the free quiz →Read the denial letter twice before doing anything else. Under the 2026 CMS rules, payers must now state a specific reason for every denied prior authorization decision (CMS, 2024). That reason tells you exactly what your appeal needs to fix.
This is the most common denial. Wegovy and Zepbound are FDA-approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity, per the FDA-approved prescribing information for each drug. Insurers often layer additional requirements on top of the FDA indication, such as a higher BMI threshold (sometimes 35 or 40), a minimum documented duration of obesity, or evidence of a structured weight-loss attempt. If your chart does not clearly show you meet the plan's specific criteria, expect this denial.
Many plans require you to try and fail one or more older or cheaper weight-management approaches before approving a GLP-1. That can include phentermine, naltrexone-bupropion, orlistat, or a documented medically supervised diet and exercise program of three to six months. A denial here means the insurer does not see evidence that step therapy was completed and documented.
Some employer plans, and most Medicare Part D plans historically, exclude anti-obesity medications as a benefit category. If your formulary lists Wegovy or Zepbound as "not covered" with no PA pathway, the denial is structural, not clinical. Appeals here often hinge on whether you have a separate covered indication.
GLP-1 medications are coded differently depending on indication. Wegovy and Zepbound use obesity diagnosis codes (E66.x), while Ozempic and Mounjaro (the type 2 diabetes versions of the same molecules) use diabetes codes (E11.x). If your prescription was sent with the wrong code or your chart does not support the code submitted, the claim is denied as miscoded. This is usually the easiest type of denial to fix.
Insurers require chart notes that establish BMI, comorbidities, prior treatment attempts, and current management plan. If your prescriber's office submitted a clean PA form but no supporting chart notes, the reviewer often denies for insufficient documentation. The fix is to attach the records on appeal.
Some plans restrict GLP-1 prescriptions to specific doses, fill quantities, or maximum durations. A denial here usually means the prescription was written outside those parameters, not that the medication is denied outright.
Two federal frameworks set the clock on your appeal.
The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) took effect January 1, 2026. Under this rule, impacted payers (Medicare Advantage, Medicaid managed care, CHIP, and Marketplace QHPs) must send prior authorization decisions within 72 hours for expedited requests and within 7 calendar days for standard requests, and must provide a specific reason for every denial (CMS, 2024). Employer self-funded plans regulated by ERISA are not directly covered by CMS-0057-F, but many voluntarily adopt similar timelines.
For ERISA-regulated employer plans (most commercial coverage), you have at least 180 days from the date of the denial notice to file an internal appeal (DOL, 29 CFR 2560.503-1). The plan then has up to 30 days to decide a pre-service appeal under ACA standards, or up to 60 days for post-service claims. Miss the 180-day filing window and the insurer is not required to accept your appeal, and you may lose the right to sue in federal court.
If your internal appeal is denied, you have up to four months from that final internal denial to request an external review through an Independent Review Organization (HealthCare.gov).
Pull out the specific clinical or administrative reason cited. Note the appeal deadline, the address or portal for filing, the documents the insurer says are required, and whether peer-to-peer review is offered. Your appeal must respond to the cited reason directly. A "not medically necessary" denial needs clinical evidence of necessity. A "step therapy not met" denial needs documentation of prior treatment attempts. Treat the denial letter as a checklist.
A peer-to-peer (P2P) review is a phone call between your prescribing clinician and a physician reviewer at the insurance company. It is often the fastest path to a reversal, particularly when the denial reflects missing clinical context rather than a hard plan exclusion. Your clinician initiates the request, typically within five business days of the denial. Many denials are overturned on the call itself without ever entering the formal written appeal process.
This step is free, fast, and low-risk. Always ask your prescriber's office to attempt it before filing written appeals. Telehealth providers vary widely in whether they will do P2P reviews. Ask before you sign up.
If the peer-to-peer fails or is not offered, file the formal internal appeal. Include:
Send by certified mail or through the insurer's appeals portal, and keep copies of everything. Under ACA standards, the plan must use a reviewer who was not involved in the initial denial and who consults with qualified medical professionals when clinical judgment is required (DOL).
If the internal appeal is denied, you have the right to an external review by an Independent Review Organization. The IRO has no relationship with your insurer, and its decision is binding on the plan (HealthCare.gov). Standard external reviews are decided within 45 days. Expedited reviews are decided within 72 hours.
The external review is your strongest leverage. IROs frequently overturn denials that insurers refuse to overturn internally, and the data the insurer used must be shared with the IRO under federal rules.
If waiting for a standard appeal would seriously jeopardize your health, request expedited review. Your clinician must certify the urgency in writing. Expedited internal appeals must be decided as soon as the medical situation requires, and expedited external reviews within 72 hours (HealthCare.gov). Urgent appeals are most defensible when there is documented metabolic instability, uncontrolled comorbidities, or a clinical reason the patient cannot wait weeks for a decision.
The strongest appeals are organized, documented, and specific. Aim to include:
Pros
Cons
Not medically necessary. Submit a letter of medical necessity that explicitly states the FDA indication, your BMI, your comorbidities, and the clinical rationale. Quote the prescribing information.
Step therapy not completed. Provide pharmacy records or chart notes showing each prior medication tried, the dose, the duration, and the reason for discontinuation. If step therapy is medically inappropriate for your case (for example, a contraindication to phentermine), have your clinician document that and request a step therapy override.
Plan exclusion. Check whether you have a separate covered indication. A patient with both obesity and type 2 diabetes may be denied for Wegovy under a weight-loss exclusion but approved for the same molecule (semaglutide as Ozempic) under a diabetes benefit. Also check whether your state has an external review pathway that can override plan exclusions in narrow circumstances.
Diagnosis code mismatch. Easiest fix. Have the prescriber resubmit with the correct code and supporting chart documentation.
Documentation incomplete. Attach the missing records to the appeal. Often the PA was denied because the form was submitted without supporting chart notes, and the appeal succeeds when the records are added.
Quantity or dose limit exceeded. Request a quantity-limit exception with clinical justification, or adjust the prescription to fit within plan parameters.
Most successful appeals require two to six weeks of active work, including gathering records, drafting the medical necessity letter, and waiting for the insurer's response. Peer-to-peer reviews can resolve in days. Internal appeals typically take 30 to 60 days. External reviews take up to 45 days for standard cases.
Not every appeal wins. The strongest cases combine a clear FDA-approved indication, documented step therapy, well-managed comorbidities, and a prescriber who will write a thorough letter of medical necessity. The hardest cases involve hard plan exclusions with no covered alternative indication.
Ro
Insurance navigation included
Helps members complete prior authorization paperwork and supports appeals documentation for Wegovy and Zepbound.
Losing an appeal does not mean losing access. As of May 2026, the manufacturer-direct cash-pay programs have become a viable backstop.
NovoCare Pharmacy sells FDA-approved Wegovy at a flat $499 per month across all titration doses, with home delivery from a contracted mail-order pharmacy (Novo Nordisk press release). Pricing is subject to change; verify the current rate on the NovoCare website before enrolling.
LillyDirect sells Zepbound single-dose vials starting at $299 per month for the 2.5 mg dose, with the 5 mg vial at $399 per month and 7.5 mg through 15 mg vials at $449 per month (Lilly pricing info). Pricing has changed multiple times in the past year, so confirm the current rate on the LillyDirect site before enrolling.
If cash-pay brand-name pricing is still out of reach, our GLP-1 without insurance guide walks through the full range of self-pay paths. Note that compounded semaglutide and tirzepatide are no longer broadly available as shortage-era alternatives the way they were in 2024 and 2025. The FDA declared the semaglutide shortage resolved, and compounded versions are now legally restricted compared to the prior window. For context on the compounded market and what is and is not currently available, see our guides on compounded vs brand-name semaglutide and is compounded semaglutide safe.
You can also revisit coverage at your next open enrollment by choosing a plan that covers GLP-1s. Our plans-that-cover-Wegovy-and-Zepbound guide covers what to look for.
Some telehealth providers will write the prescription and leave the paperwork to you. Others actively support members through prior authorization and appeals. If you are facing a denial and want professional help with the documentation, Ro and PlushCare are the two providers in our network most active on insurance support. Found also offers brand-name medications with insurance navigation. If you would rather skip insurance entirely after an appeal failure, NovoCare Pharmacy and LillyDirect sell FDA-approved Wegovy and Zepbound respectively without going through a benefits cycle.
For the upstream view of how to get an initial prior authorization approved the first time, see our companion article on getting prior authorization for Wegovy or Zepbound.
A denial is a starting point, not an ending. The federal appeal framework exists because reviewers get decisions wrong. Use it.